newsfilter
← Latest News
GlobeNewswire·

Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter Company increases 2022 Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million and narrows non-GAAP adjusted